» Authors » Tom Borge Johannesen

Tom Borge Johannesen

Explore the profile of Tom Borge Johannesen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 85
Citations 1773
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Otrebski Nilsson M, Aas K, Myklebust T, Gjelsvik Y, Haug E, Fossa S, et al.
Scand J Urol . 2023 Dec; 58:133-140. PMID: 38116675
In comparable men with non-metastatic prostate cancer, radical prostatectomy (RP), radiotherapy (RAD) and active surveillance (AS) are treatment options with similar survival rates, but different side-effects. Healthcare professionals consider pretreatment...
12.
Laronningen S, Skog A, Engholm G, Ferlay J, Johannesen T, Kristiansen M, et al.
Front Oncol . 2023 Aug; 13:1098342. PMID: 37614501
Aim Of The Article: We present our new GDPR-compliant federated analysis programme (nordcan.R), how it is used to compute statistics for the Nordic cancer statistics web platform NORDCAN, and demonstrate...
13.
Johansson A, Skog A, Johannesen T, Myklebust T, Skovlund C, Morch L, et al.
Lancet Reg Health Eur . 2023 Aug; 31:100680. PMID: 37547277
Background: In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population. Methods: In nationwide...
14.
Haug E, Myklebust T, Juliebo-Jones P, Reisaeter L, Aas K, Berg A, et al.
BJUI Compass . 2023 Apr; 4(3):331-338. PMID: 37025477
Objectives: The aim of this study is to evaluate the 2015 introduction of prebiopsy magnetic resonance imaging of the prostate (MRI-P) as the standard of care for diagnosing prostate cancer...
15.
Lundberg F, Kroman N, Lambe M, Andersson T, Engholm G, Johannesen T, et al.
Acta Oncol . 2022 Dec; 61(12):1481-1489. PMID: 36542678
Background: A recent overview of cancer survival trends 1990-2016 in the Nordic countries reported continued improvements in age-standardized breast cancer survival among women. The aim was to estimate age-specific survival...
16.
Helland A, Andersen K, Myklebust T, Johannesen T, Aaroe J, Enerly E
Cancer Treat Res Commun . 2022 Sep; 33:100636. PMID: 36155129
Background: Testing for epidermal growth factor receptor mutation (EGFRm) status is a prerequisite to identify eligible patients for tyrosine kinase inhibitors (TKI) treatment. However, EGFR testing of patients with non-small...
17.
Fossa S, Dahl A, Johannesen T, Gjelsvik Y, Storas A, Myklebust T
Clin Transl Radiat Oncol . 2022 Sep; 37:78-84. PMID: 36093341
Background: Few studies have described the impact of urinary, bowel and sexual Adverse Health Outcomes (AHOs) on Quality of Life (QoL) in Prostate Cancer Survivors living for more than 5 ...
18.
Deltour I, Poulsen A, Johansen C, Feychting M, Johannesen T, Auvinen A, et al.
Environ Int . 2022 Aug; 168:107487. PMID: 36041243
Introduction: In the Nordic countries, the use of mobile phones increased sharply in the mid-1990s especially among middle-aged men. We investigated time trends in glioma incidence rates (IR) with the...
19.
Johansson A, Laronningen S, Skovlund C, Kristiansen M, Morch L, Friis S, et al.
Int J Cancer . 2022 Apr; 151(3):381-395. PMID: 35419824
The severity of the COVID-19 pandemic and subsequent mitigation strategies have varied across the Nordic countries. In a joint Nordic population-based effort, we compared patterns of new cancer cases and...
20.
Jonsson V, Awan H, Jones N, Johannesen T, Thogersen K, Steig B, et al.
Sci Rep . 2022 Apr; 12(1):6138. PMID: 35413962
The heredity of the malignant blood disorders, leukemias, lymphomas and myeloma, has so far been largely unknown. The present study comprises genealogical investigations of one hundred and twelve Scandinavian families...